Log in

NASDAQ:BEAT - BioTelemetry Stock Price, Forecast & News

$45.01
-3.00 (-6.25 %)
(As of 02/28/2020 06:00 AM ET)
Today's Range
$40.00
Now: $45.01
$47.99
50-Day Range
$45.01
MA: $51.88
$55.27
52-Week Range
$37.07
Now: $45.01
$76.25
Volume878,763 shs
Average Volume195,354 shs
Market Capitalization$1.53 billion
P/E Ratio54.89
Dividend YieldN/A
Beta1.3
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments. The Healthcare segment focuses on the remote cardiac monitoring to identify arrhythmias or heart rhythm disorders. Read More…

Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BEAT
CUSIPN/A
Phone610-729-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$439.11 million
Cash Flow$3.08 per share
Book Value$9.32 per share

Profitability

Net Income$42.82 million

Miscellaneous

Employees1,500
Market Cap$1.53 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.


BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry Inc (NASDAQ:BEAT) issued its earnings results on Wednesday, February, 26th. The medical research company reported $0.48 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.48. The medical research company had revenue of $112.03 million for the quarter, compared to the consensus estimate of $110.35 million. BioTelemetry had a net margin of 6.80% and a return on equity of 20.52%. View BioTelemetry's Earnings History.

When is BioTelemetry's next earnings date?

BioTelemetry is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for BioTelemetry.

What price target have analysts set for BEAT?

6 brokers have issued 1 year target prices for BioTelemetry's stock. Their forecasts range from $54.00 to $82.00. On average, they expect BioTelemetry's stock price to reach $70.67 in the next year. This suggests a possible upside of 57.0% from the stock's current price. View Analyst Price Targets for BioTelemetry.

What is the consensus analysts' recommendation for BioTelemetry?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTelemetry.

Has BioTelemetry been receiving favorable news coverage?

News stories about BEAT stock have trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioTelemetry earned a news impact score of 3.0 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for BioTelemetry.

Are investors shorting BioTelemetry?

BioTelemetry saw a increase in short interest in February. As of February 14th, there was short interest totalling 3,040,000 shares, an increase of 7.4% from the January 30th total of 2,830,000 shares. Based on an average trading volume of 236,100 shares, the days-to-cover ratio is currently 12.9 days. Approximately 9.2% of the company's shares are sold short. View BioTelemetry's Current Options Chain.

Who are some of BioTelemetry's key competitors?

Some companies that are related to BioTelemetry include Acadia Healthcare (ACHC), Hanger (HNGR), Biocorrx (BICX), AAC (AAC) and IMAC (IMAC).

What other stocks do shareholders of BioTelemetry own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA), Micron Technology (MU), Square (SQ), Netflix (NFLX), Paypal (PYPL), Alibaba Group (BABA), ABIOMED (ABMD), Adobe (ADBE), Canopy Growth (CGC) and Advanced Micro Devices (AMD).

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the folowing people:
  • Mr. Joseph H. Capper, CEO, Pres & Director (Age 55)
  • Ms. Heather C. Getz, Exec. VP & CFO (Age 44)
  • Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Fred Broadway III, Pres of BioTel Heart (Age 49)
  • Mr. Daniel M. Wisniewski, Sr. VP of Technical Operations (Age 55)

Who are BioTelemetry's major shareholders?

BioTelemetry's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (10.17%), Credit Suisse AG (3.21%), State Street Corp (2.92%), Loomis Sayles & Co. L P (1.75%), Pembroke Management LTD (1.63%) and Rothschild & Co. Asset Management US Inc. (1.63%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

Which institutional investors are selling BioTelemetry stock?

BEAT stock was sold by a variety of institutional investors in the last quarter, including THB Asset Management, Vident Investment Advisory LLC, Millrace Asset Group Inc., Rothschild & Co. Asset Management US Inc., Principal Financial Group Inc., Arizona State Retirement System, Pinebridge Investments L.P. and Public Sector Pension Investment Board. Company insiders that have sold BioTelemetry company stock in the last year include Kirk E Gorman and Peter Ferola. View Insider Buying and Selling for BioTelemetry.

Which institutional investors are buying BioTelemetry stock?

BEAT stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Pembroke Management LTD, Loomis Sayles & Co. L P, Kirr Marbach & Co. LLC IN, Barclays PLC, Royce & Associates LP, Walthausen & Co. LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for BioTelemetry.

How do I buy shares of BioTelemetry?

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BEAT stock can currently be purchased for approximately $45.01.

How big of a company is BioTelemetry?

BioTelemetry has a market capitalization of $1.53 billion and generates $439.11 million in revenue each year. The medical research company earns $42.82 million in net income (profit) each year or $1.95 on an earnings per share basis. BioTelemetry employs 1,500 workers across the globe.View Additional Information About BioTelemetry.

What is BioTelemetry's official website?

The official website for BioTelemetry is http://www.gobio.com/.

How can I contact BioTelemetry?

BioTelemetry's mailing address is 1000 CEDAR HOLLOW ROAD, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected]


MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  319 (Vote Underperform)
Total Votes:  682
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel